Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Research

Depressive Symptoms and Quality of Life in Adolescents With Type 2 Diabetes

Baseline data from the TODAY study

  1. Barbara J. Anderson, PHD1⇓,
  2. Sharon Edelstein, SCM2,
  3. Natalie Walders Abramson, PHD3,
  4. Lorraine E. Levitt Katz, MD4,
  5. Patrice M. Yasuda, PHD5,
  6. Sylvia J. Lavietes, MS6,
  7. Paula M. Trief, PHD7,
  8. Sherida E. Tollefsen, MD8,
  9. Siripoom Vudhipoom McKay, MD9,
  10. Patricia Kringas, RN, MA, CDE10,
  11. Terri Lynn Casey, BSN, RN, CDE11 and
  12. Marsha D. Marcus, PHD12
  1. 1Department of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston, Texas
  2. 2George Washington University Biostatistics Center, Rockville, Maryland
  3. 3Department of Psychiatry and Behavioral Sciences, The Children’s Hospital, University of Colorado Denver School of Medicine, Aurora, Colorado
  4. 4Division of Endocrinology, Children’s Hospital of Philadelphia/University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
  5. 5Center for Endocrinology, Diabetes & Metabolism, Children’s Hospital Los Angeles, Los Angeles, California
  6. 6Department of Pediatric Diabetes, Yale University, New Haven, Connecticut
  7. 7Departments of Psychiatry and Medicine, SUNY Upstate Medical University, Syracuse, New York
  8. 8Department of Pediatrics, Saint Louis University Health Sciences Center, St. Louis, Missouri
  9. 9Department of Pediatric Endocrinology and Metabolism, Baylor College of Medicine, Houston, Texas
  10. 10Naomi Berrie Diabetes Center, Columbia University Medical Center, New York, New York
  11. 11Pediatric Diabetes, Endocrinology and Metabolism, University Hospitals Case Medical Center, Cleveland, Ohio
  12. 12Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
  1. Corresponding author: Barbara J. Anderson, bja{at}bcm.edu.
Diabetes Care 2011 Oct; 34(10): 2205-2207. https://doi.org/10.2337/dc11-0431
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE The study objective was to examine the prevalence of depressive symptoms and relationships to quality of life and demographics in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study’s large, ethnically diverse youth with type 2 diabetes.

RESEARCH DESIGN AND METHODS A total of 704 youth with type 2 diabetes <2 years’ duration, aged 10–17 years, and BMI ≥85th percentile completed depressive symptoms and quality of life measures.

RESULTS Some 14.8% reported clinically significant depressive symptoms, and older girls had significantly higher rates than older boys.

CONCLUSIONS Rates of significant depressive symptoms were similar to those of healthy adolescents and lower than those of teens with type 1 diabetes. Elevated depressive symptoms, particularly in older girls, suggest clinicians assess vulnerability.

Little is known about physiologic and psychosocial correlates of type 2 diabetes in adolescents, whereas data on adults with type 2 diabetes are available, with rates of depressive symptoms approximately twice as high as for adults without diabetes (1), underscoring the importance of examining depressive symptoms in adolescents with type 2 diabetes. Depression in adults is also associated with significant psychosocial and physical complications (2). To date, we have not had access to large samples of patients needed to study depression systematically in youth with type 2 diabetes. Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) offers unique data concerning the psychosocial functioning of youth with type 2 diabetes.

RESEARCH DESIGN AND METHODS

Participants

The TODAY study design and participant characteristics have been reported (3). The protocol was approved by an External Evaluation Committee convened by the National Institute of Diabetes and Digestive and Kidney Diseases and by institutional review boards of each participating institution. Participants provided informed consent or assent.

Procedures

Eligible youth and an adult caregiver were recruited at 15 TODAY clinical centers (Supplementary Data). Relevant to the current report, youth were ineligible if diagnosed with major depression or if taking psychotropic medications. Before baseline, youth successfully completed a run-in phase lasting 8–24 weeks, during which youth had to establish blood glucose HbA1c <8% on metformin alone. Of the 927 youth who entered run-in, 704 (76%) successfully completed run-in and provided baseline data; 55 youth (5.9%) were not able to maintain glycemic control on metformin alone. Average HbA1c at baseline was 5.9% (5.5–6.5). Detailed clinical characteristics of the TODAY cohort at baseline have been reported (3).

Depressive symptoms.

The Children’s Depression Inventory (CDI) (4), assessing depressive symptoms, was completed by participants aged ≤15 years. Items are combined into a total depressive symptom score. A cutoff score ≥13 identifies clinically significant levels of depressive symptoms (4).

The Beck Depression Inventory II (BDI-II) (5) was completed by participants aged ≥16 years. Items are combined into a total score, with a cutoff score ≥14 to identify a clinically significant level of depressive symptoms. Scores ≥29 are suggestive of “severe” depressive symptoms.

Quality of life.

Pediatric Quality of Life (PedsQL) (6) measures the youth’s perception of quality of life. The 23 items are scored using a five-point Likert scale; a total score is the average of all items.

Statistical methods

Descriptive statistics at randomization are reported as means, SDs, or percents above cutoffs for serious level of depressive symptoms. Analysis of variance or t tests were used to compare mean depressive symptoms and χ2 tests for percent above predefined cut points, by sex and race/ethnic group. Pearson correlation coefficients were used to compare the relationship between depressive symptoms and quality of life.

RESULTS

The demographic characteristics of the 704 youth randomized in TODAY have been reported (3). Briefly, girls comprised 65% of the sample, and 61% were aged 12–15 years. More than 80% reported minority race/ethnicity. Participants were overweight or obese, with 87% having a BMI >95th percentile for age and sex. Socioeconomic status was low, with >25% from homes in which neither parent had a high school diploma.

As shown in Table 1, 14.8% of youth reported depressive symptoms above the threshold for clinical significance. No differences in depressive symptom scores were seen across race/ethnicity; however, there were differences by sex (Table 1). BDI was significantly higher in older girls than in older boys, as was the percent scoring at or above the cutoff score for BDI and for CDI and BDI combined. No differences were found in the PedsQL or CDI for either race/ethnicity or sex. Both CDI and BDI were negatively correlated with PedsQL, −0.59 for the CDI and −0.63 for the BDI (both P < 0.001).

View this table:
  • View inline
  • View popup
Table 1

Mean (SD) scores on the PedsQL, CDI (youth aged ≤15 years), and BDI (youth aged ≥16 years), and percent scoring at or above the cutoff score for “serious level of depressive symptoms” on each inventory and for combined CDI and BDI by racial/ethnic group and by sex

CONCLUSIONS

In the TODAY cohort, ∼l5% scored at or above the cutoff for clinically significant depressive symptoms, a rate similar to that of adolescents without type 2 diabetes (7). Depressive symptoms were not assessed before run-in. Thus, although it is not possible to rule out that completion of run-in had some psychologic benefits for participants, with respect to demographic and depressive symptom characteristics, the TODAY cohort at baseline was similar to youth with type 2 diabetes in the population-based SEARCH for Diabetes in Youth Study (SEARCH) (8,9).

Older female adolescents reported more depressive symptoms in comparison with younger girls and with boys. A post hoc analysis revealed that only a small number of older youth (n = 11, all girls; 1.6%) scored at or above the usual cutoff score (≥29) for “severe” depressive symptoms. This pattern is similar to that of population samples where rates of depression are approximately the same for boys and girls during childhood, but diverge during adolescence when girls have depression rates two to three times higher than boys (10). Current results also are similar to those reported in the SEARCH study, which found that being female and older were risk factors for higher rates of depressive symptoms (11).

Depression is the most studied psychosocial factor in adolescents with type 1 diabetes, with prevalence rates for increased risk of elevated depressive symptoms reported between 14 and 33% (12,13). The risk for depression increases as adolescents with type 1 diabetes develop into young adulthood, with Kovacs et al. (14) reporting that half of young adults with type 1 diabetes followed since adolescence developed a depressive or anxiety disorder.

There were no significant differences in depressive symptom or quality of life scores across racial/ethnic groups in either age-group. As expected, lower quality of life scores were significantly related to higher rates of depressive symptoms in both age-groups.

Because of the study design, at baseline the TODAY sample was relatively homogeneous, which may limit generalizability. Youth had low socioeconomic status and were predominately minorities, overweight/obese, and in adequate glycemic control at baseline. As the TODAY cohort becomes more heterogeneous over time with respect to glycemic control, BMI, and adherence, baseline depressive symptoms may become important predictors of subsequent treatment outcomes.

Although sample homogeneity is regarded as a study limitation, it is important to note that despite adequate glycemic control at baseline a large percentage of participants also had serious metabolic abnormalities present (3). Moreover, the sex, age, racial/ethnic groups, socioeconomic level, and depressive symptom characteristics of the TODAY cohort are similar to the those of the population-based SEARCH study (8,9), which suggests that the TODAY cohort is representative of the population of youth with type 2 diabetes in the U.S.

Type 2 diabetes doubles the risk of depression in adults, with less than 25% receiving adequate depression treatment (15). Given the serious negative physical and psychosocial complications in depressed adults with type 2 diabetes (2,15), clinicians caring for older youth with type 2 diabetes should be familiar with mental health resources. Given the trajectory documented in adolescents with type 1 diabetes and high depressive symptoms for these symptoms to worsen as the older teen transitions into young adulthood, it is imperative to monitor and refer older adolescents with type 2 diabetes and depressive symptoms.

Acknowledgments

This work was completed with funding from the National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health grants U01-DK-61212, U01-DK-61230, U01-DK-61239, U01-DK-61242, and U01-DK-61254; from the National Center for Research Resources General Clinical Research Centers Program grants M01-RR00036 (Washington University School of Medicine), M01-RR00043-45 (Children’s Hospital Los Angeles), M01-RR00069 (University of Colorado Denver), M01-RR00084 (Children’s Hospital of Pittsburgh), M01-RR01066 (Massachusetts General Hospital), M01-RR00125 (Yale University), and M01-RR14467 (University of Oklahoma Health Sciences Center); and from the National Center for Research Resources Clinical and Translational Science Awards grants UL1-RR024134 (Children’s Hospital of Philadelphia), UL1-RR024139 (Yale University), UL1-RR024153 (Children’s Hospital of Pittsburgh), UL1-RR024989 (Case Western Reserve University), UL1-RR024992 (Washington University), UL1-RR025758 (Massachusetts General Hospital), and UL1-RR025780 (University of Colorado Denver).

No potential conflicts of interest relevant to this article were reported.

The writing group takes responsibility for the content of this article: B.J.A. (chair), S.E., N.W.A., L.E.L.K., P.M.Y., P.M.T., S.E.T., S.V.M., T.L.C., and M.D.M. A list of the members of the TODAY Study Group can be found in the Supplementary Data online.

B.J.A. and S.E. researched data, contributed to discussion, wrote the manuscript, and reviewed and edited the manuscript. N.W.A. contributed to discussion and reviewed and edited the manuscript. L.E.L.K. wrote, reviewed, and edited the manuscript. P.M.Y. researched data, contributed to discussion, and reviewed and edited the manuscript. S.J.L. researched data and contributed to discussion. P.M.T., S.E.T., and S.V.M. researched data, contributed to discussion, and reviewed and edited the manuscript. P.K. reviewed and edited the manuscript. T.L.C. researched data, contributed to discussion, and reviewed and edited the manuscript. M.D.M. contributed to discussion and reviewed and edited the manuscript.

Parts of this study were presented in abstract form at the 70th Scientific Sessions of the American Diabetes Association, Orlando, Florida, 25–29 June 2010.

The TODAY Study Group thanks the American Diabetes Association and the following companies for donations in support of the study’s efforts: Becton, Dickinson and Company; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; LifeScan, Inc.; Pfizer; and sanofi-aventis.

Footnotes

  • Clinical trial reg. no. NCT00081328, clinicaltrials.gov.

  • This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0431/-/DC1.

  • A list of the members of the TODAY Study Group can be found in the Supplementary Data online.

  • Received March 3, 2011.
  • Accepted July 1, 2011.
  • © 2011 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

References

  1. ↵
    1. Anderson RJ,
    2. Freedland KE,
    3. Clouse RE,
    4. Lustman PJ
    . The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:1069–1078pmid:11375373
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Lin EHB,
    2. Rutter CM,
    3. Katon W,
    4. et al
    . Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care 2010;33:264–269pmid:19933989
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Copeland KC,
    2. Zeitler P,
    3. Geffner M,
    4. et al
    . Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 2011;96:159–167pmid:20962021
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Kovacs M
    . Children’s Depression Inventory. New York, Multi-Health Systems, 1992
  5. ↵
    1. Beck AT,
    2. Steer RA,
    3. Brown GK
    . Manual for the Beck Depression Inventory-II. San Antonio, TX, Psychological Corporation, 1996
  6. ↵
    1. Varni JW,
    2. Seid M,
    3. Rode CA
    . The PedsQL: measurement model for the Pediatric Quality of Life inventory. Med Care 1999;37:126–139pmid:10024117
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Kessler RC,
    2. Avenevoli S,
    3. Ries Merikangas K
    . Mood disorders in children and adolescents: an epidemiologic perspective. Biol Psychiatry 2001;49:1002–1014pmid:11430842
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Dabelea D,
    2. Bell RA,
    3. D’Agostino RB Jr,
    4. et al.
    ; Writing Group for the SEARCH for Diabetes in Youth Study Group. Incidence of diabetes in youth in the United States. JAMA 2007;297:2716–2724pmid:17595272
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Liese AD,
    2. D’Agostino RB Jr,
    3. Hamman RF,
    4. et al.
    ; SEARCH for Diabetes in Youth Study Group. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006;118:1510–1518pmid:17015542
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Hankin BL,
    2. Abramson LY,
    3. Moffitt TE,
    4. Silva PA,
    5. McGee R,
    6. Angell KE
    . Development of depression from preadolescence to young adulthood: emerging gender differences in a 10-year longitudinal study. J Abnorm Psychol 1998;107:128–140pmid:9505045
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Lawrence JM,
    2. Standiford DA,
    3. Loots B,
    4. et al.
    ; SEARCH for Diabetes in Youth Study. Prevalence and correlates of depressed mood among youth with diabetes: the SEARCH for Diabetes in Youth study. Pediatrics 2006;117:1348–1358pmid:16585333
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Grey M,
    2. Whittemore R,
    3. Tamborlane W
    . Depression in type 1 diabetes in children: natural history and correlates. J Psychosom Res 2002;53:907–911pmid:12377302
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Hood KK,
    2. Huestis S,
    3. Maher A,
    4. Butler D,
    5. Volkening L,
    6. Laffel LM
    . Depressive symptoms in children and adolescents with type 1 diabetes: association with diabetes-specific characteristics. Diabetes Care 2006;29:1389–1391pmid:16732028
    OpenUrlFREE Full Text
  14. ↵
    1. Kovacs M,
    2. Obrosky DS,
    3. Goldston D,
    4. Drash A
    . Major depressive disorder in youths with IDDM. A controlled prospective study of course and outcome. Diabetes Care 1997;20:45–51pmid:9028692
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Rubin RR,
    2. Ciechanowski P,
    3. Egede LE,
    4. Lin EH,
    5. Lustman PJ
    . Recognizing and treating depression in patients with diabetes. Curr Diab Rep 2004;4:119–125pmid:15035972
    OpenUrlPubMed
View Abstract
Back to top
Diabetes Care: 42 (12)

Current Issue

December 2019
Volume 42, Issue 12

  • Current Issue
  • Index by Author
  • Issue Archive
  • Podcasts
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Depressive Symptoms and Quality of Life in Adolescents With Type 2 Diabetes
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
Citation Tools
Depressive Symptoms and Quality of Life in Adolescents With Type 2 Diabetes
Barbara J. Anderson, Sharon Edelstein, Natalie Walders Abramson, Lorraine E. Levitt Katz, Patrice M. Yasuda, Sylvia J. Lavietes, Paula M. Trief, Sherida E. Tollefsen, Siripoom Vudhipoom McKay, Patricia Kringas, Terri Lynn Casey, Marsha D. Marcus
Diabetes Care Oct 2011, 34 (10) 2205-2207; DOI: 10.2337/dc11-0431

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Depressive Symptoms and Quality of Life in Adolescents With Type 2 Diabetes
Barbara J. Anderson, Sharon Edelstein, Natalie Walders Abramson, Lorraine E. Levitt Katz, Patrice M. Yasuda, Sylvia J. Lavietes, Paula M. Trief, Sherida E. Tollefsen, Siripoom Vudhipoom McKay, Patricia Kringas, Terri Lynn Casey, Marsha D. Marcus
Diabetes Care Oct 2011, 34 (10) 2205-2207; DOI: 10.2337/dc11-0431
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Research

  • Suicide Risk Assessment in Youth and Young Adults With Type 1 Diabetes
  • Plasma Lipidome and Prediction of Type 2 Diabetes in the Population-Based Malmö Diet and Cancer Cohort
  • Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Show more Original Research

Clinical Care/Education/Nutrition/Psychosocial Research

  • Changes in Consumption of Sugary Beverages and Artificially Sweetened Beverages and Subsequent Risk of Type 2 Diabetes: Results From Three Large Prospective U.S. Cohorts of Women and Men
  • Genetic Prediction of Serum 25-Hydroxyvitamin D, Calcium, and Parathyroid Hormone Levels in Relation to Development of Type 2 Diabetes: A Mendelian Randomization Study
  • One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System
Show more Clinical Care/Education/Nutrition/Psychosocial Research

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • BMJ Open - Diabetes Research & Care
  • Standards of Medical Care in Diabetes
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2019 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.